12,372 trials
Female Infertility
Primary: Percentage of Participants Being Pregnant as Measured by the Presence of Fetal Heart Beats at 12 Weeks´Gestation Using Transvaginal Ultrasound — 37.6; 33.1 percentage of…
Rheumatoid Arthritis
Primary: Number of Patients Experiencing Anaphylactic Reactions — 0; 1 Participants
Pulmonary Arterial Hypertension
Primary: Percentage of Subjects With Sustained Treatment Transition — 82.4 Percentage of participants
Tetanus · Acellular Pertussis · Diphtheria
Primary: Number of Seroprotected Subjects for Anti-diphtheria (Anti-D) and Anti-tetanus (Anti-T). — 35; 115; 35; 115 Participants
Arrhythmia
Primary: The Number of Participants With Atrial Fibrillation — 26; 37 Participants
Multiple Sclerosis, Primary Progressive
Primary: Time to Onset of Clinical Disability Progression (CDP) Sustained for at Least 12 Weeks During the Double-Blind Treatment Period — NA; NA weeks
Chronic Obstructive Pulmonary Disease
Primary: Change From Baseline in Forced Expiratory Volume (FEV1) Area Under the Curve (AUC) 0-24h — 0.2321; 0.2436 Liters — p=0.139
Risperidone-induced Hyperprolactinemia
Primary: Trabecular Bone Mineral Density in the Ultradistal Radius — 192.9; 197.2; 191.0; 194.6 mg/cm^3
Rheumatoid Arthritis
Primary: Change From Week 24 in Disease Activity Score Based on 28 Joints (DAS28) Score at Week 40 — 2.13; 2.11; 0.15; 0.48 units on a scale
Heart Failure
Primary: Interval Changes in Peak Oxygen Consumption (VO2) — 14.05; 14.45; 13.3; 14.85 mL/kg/min — p=>0.20
Prevention of : Herpes-Zoster
Primary: Geometric Mean Titer (GMT) of Varicella Zoster Virus (VZV) Antibodies 4 Weeks After Each Vaccination: Groups 2 and 3 — 498.8; 523.3; 555.3; 410.5 gpELISA units/mL…
Breast Cancer Metastatic · BRCA 1 Gene Mutation · BRCA 2 Gene Mutation
Primary: Progression-free Survival (PFS) Using Blinded Independent Central Review (BICR) According to Modified Response Evaluation Criteria In Solid Tumours (RECIST v1.1) — 7.0…
Head and Neck Cancer
Primary: Progression-free Survival (PFS) (3-year Rate Reported) — 61.2; 58.9 percentage of participants — p=0.76
Arthritis, Psoriatic
Primary: Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 14 — 21.8; 75.1 Percentage of Participants — p=<0.001
Thrombosis, Venous
Primary: Percentage of Participants With Venous Thromboembolism (VTE) During Efficacy Period — 8.3; 2.2 percentage of participants